📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
84 announcements match the current filters (relevance ≥ 5).
Lupin Launches Generic Xigduo XR Tablets in the United States
Lupin Limited has announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market. This product is a generic version of AstraZeneca's Xigduo XR, indicated for the treatment of type 2 diabetes. The launch follows the approval of Lupin's Abbreviated New Drug Application (ANDA) by the U.S. FDA. This expansion strengthens Lupin's existing anti-diabetic portfolio in its key U.S. market.
Key Highlights
Launch of generic Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Product is bioequivalent to AstraZeneca's Xigduo XR
Available in four strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg
Strengthens Lupin's position in the U.S. anti-diabetic therapy segment
👀 What to Watch
Investors should monitor the ramp-up of this product as it contributes to Lupin's U.S. generic revenue stream. The successful launch of complex generics and chronic therapy products remains a key growth driver for the company.
Lupin's Somerset Facility Receives US FDA Form-483 with 3 Observations
The U.S. FDA conducted an inspection of Lupin's manufacturing facility in Somerset, New Jersey, from April 13 to April 17, 2026. The inspection concluded with the issuance of a Form-483 containing three observations. Lupin has committed to addressing these observations and responding to the regulator within the stipulated timeframe. While the number of observations is relatively low, the company's ability to resolve them without further escalation is critical for its U.S. operations.
Key Highlights
Inspection conducted at the Somerset, New Jersey facility from April 13 to April 17, 2026
U.S. FDA issued a Form-483 with 3 specific observations upon conclusion of the audit
Lupin is required to submit a formal response to the observations within the regulatory timeframe
The facility's compliance status is vital for maintaining current supply and future product approvals in the U.S. market
👀 What to Watch
Investors should monitor for the FDA's final classification of the inspection; while 3 observations are manageable, any escalation to an OAI status could impact the stock's valuation.
Lupin Subsidiary Settles US Antitrust Lawsuit with Humana for USD 30 Million
Lupin's US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has entered into a settlement agreement with Humana Inc. to resolve civil lawsuits alleging anticompetitive behavior. Under the agreement, LPI will pay USD 30 million to settle all claims related to the 'In Re Generic Pharmaceuticals Antitrust Litigation'. Crucially, the company stated that this settlement amount has already been provided for in prior consolidated financial results, meaning no new impact on current earnings. The settlement allows Lupin to avoid the costs and uncertainties of continued litigation while maintaining its denial of any liability.
Key Highlights
Lupin Pharmaceuticals, Inc. USA to pay USD 30 million to Humana Inc. as part of a settlement agreement.
The settlement amount was already accounted for in the company's previous consolidated financial statements.
The litigation involved allegations of federal and state antitrust law violations in the US generic market.
Agreement provides a full and final release of all claims against LPI, its parents, affiliates, and officers.
LPI continues to deny all allegations and the settlement does not imply admission of liability.
👀 What to Watch
Investors should view this as a positive resolution of a legal overhang, particularly as the financial impact was already provisioned. No immediate action is required as the settlement does not affect future cash flows beyond what was already anticipated.
Lupin Launches Generic Dapagliflozin Tablets (5 mg and 10 mg) in the United States
Lupin Limited has announced the commercial launch of Dapagliflozin Tablets in the United States market in 5 mg and 10 mg strengths. This launch follows the U.S. FDA approval of Lupin's Abbreviated New Drug Application (ANDA), establishing the product as a bioequivalent to AstraZeneca's Farxiga®. The product targets the anti-diabetic segment, which is a core therapeutic area for Lupin. This move is expected to strengthen Lupin's generic portfolio and revenue potential in the North American market.
Key Highlights
Launch of Dapagliflozin Tablets in 5 mg and 10 mg strengths in the US market.
Received U.S. FDA approval for ANDA as a bioequivalent to the reference brand Farxiga®.
Strengthens Lupin's position in the anti-diabetic therapy area across its 100+ global markets.
The launch leverages Lupin's extensive infrastructure of 15 manufacturing sites and 7 research centers.
👀 What to Watch
Investors should view this as a positive development for Lupin's US generic business. Monitor the company's upcoming quarterly results for the revenue contribution and market share gains from this specific launch.
Lupin Receives U.S. FDA Approval for Generic Xigduo XR Tablets
Lupin Limited has received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets. The approval covers four specific strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg. Additionally, the company received tentative approval for the 2.5 mg/1,000 mg strength. This product is a bioequivalent version of AstraZeneca's Xigduo XR, targeting the significant anti-diabetic market in the United States.
Key Highlights
Received U.S. FDA approval for four strengths of Dapagliflozin and Metformin Hydrochloride ER Tablets
Obtained tentative approval for the 2.5 mg/1,000 mg strength of the same formulation
Product is a generic version of AstraZeneca's Xigduo XR, a major branded anti-diabetic drug
Strengthens Lupin's presence in the U.S. market for chronic therapy areas like diabetes
Lupin operates 15 manufacturing sites and 7 research centers globally to support such launches
👀 What to Watch
Investors should view this as a positive step in Lupin's U.S. generic strategy, likely contributing to revenue growth in the anti-diabetic segment. Monitor the commercial launch timeline and potential market share capture from the innovator.
Lupin Completes Acquisition of VISUfarma; Adds €53m Revenue Portfolio
Lupin Limited has successfully completed the acquisition of VISUfarma B.V., a European specialty pharmaceutical firm focused on ophthalmology. The acquisition brings over 60 branded products into Lupin's portfolio, covering areas like dry eye, glaucoma, and retinal health. VISUfarma reported revenues of €53 million in 2025 and maintains a strong commercial presence in Italy, the UK, Spain, Germany, and France. This strategic move is expected to be immediately accretive to Lupin's earnings and significantly strengthens its specialty care footprint in the European market.
Key Highlights
Acquisition adds a portfolio of over 60 branded ophthalmology products across Europe
VISUfarma generated €53 million in revenue during the 2025 calendar year
Expands Lupin's commercial footprint in 5 major European markets: Italy, UK, Spain, Germany, and France
Management confirms the acquisition is immediately accretive to the company's financial performance
👀 What to Watch
Investors should view this as a positive strategic expansion into high-margin specialty segments. Monitor the integration progress and the incremental contribution to the European business segment in upcoming quarterly results.
Lupin to Acquire 43.38% Stake in Multicare Philippines for USD 39.6 Million
Lupin's subsidiary, Nanomi B.V., has signed a definitive agreement to acquire a 43.38% minority stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI) for a cash consideration not exceeding USD 39.6 million. Nanomi already holds a 56.28% stake in the entity, and this acquisition is a strategic move to eventually make MPPI a wholly-owned subsidiary. MPPI is a key player in the Philippines pharmaceutical market, reporting a turnover of PHP 2,096.6 million for FY25. The transaction is expected to be completed by May 2026, facilitating better operational integration and strategic flexibility in emerging markets.
Key Highlights
Acquisition of 11,794,497 shares representing 43.38% of the total paid-up shares of MPPI.
Total cash consideration for the minority stake is capped at USD 39.6 million.
MPPI reported a turnover of PHP 2,096.6 million and a net worth of PHP 1,265.5 million as of March 31, 2025.
The deal aims to consolidate Lupin's presence in the Philippines and unlock long-term value through full ownership.
👀 What to Watch
Investors should view this as a positive consolidation move that strengthens Lupin's emerging market portfolio. Monitor the completion of the deal by May 2026 and its subsequent impact on consolidated bottom-line growth.
Lupin Completes Acquisition of Netherlands-based VISUfarma B.V.
Lupin Limited, through its wholly owned subsidiary Nanomi B.V., has successfully completed the acquisition of 100% share capital of VISUfarma B.V., Netherlands. The deal, which was initially announced in September 2025, reached completion on April 1, 2026, after fulfilling all customary closing conditions. Consequently, VISUfarma and its subsidiaries have now become wholly owned step-down subsidiaries of Lupin. This acquisition is expected to bolster Lupin's footprint in the European pharmaceutical market.
Key Highlights
Acquisition of 100% share capital of VISUfarma B.V. finalized on April 1, 2026
Transaction executed via Nanomi B.V., a wholly owned subsidiary of Lupin Limited
VISUfarma and its subsidiaries are now step-down subsidiaries of the company
Follows a series of regulatory updates starting from the definitive agreement in September 2025
👀 What to Watch
Investors should view this as a positive step in Lupin's international expansion strategy and monitor the subsequent impact on European revenue. No immediate action is required, but the integration of VISUfarma's portfolio will be a key metric to watch in upcoming quarterly results.
Lupin Receives Tentative U.S. FDA Approval for Sugammadex Injection
Lupin Limited has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Sugammadex Injection, available in 200 mg/2 mL and 500 mg/5 mL strengths. The product is a generic version of Merck's Bridion, used to reverse neuromuscular blockade in surgical patients aged 2 years and older. While a tentative approval indicates the product meets safety and efficacy standards, it cannot be marketed until patent or exclusivity issues are resolved. This approval strengthens Lupin's future injectable pipeline in the critical U.S. hospital segment.
Key Highlights
Received tentative U.S. FDA approval for Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL).
Product is bioequivalent to Merck’s Bridion Injection, a major brand in the neuromuscular reversal market.
Indicated for use in both adult and pediatric patients (2 years and older) undergoing surgery.
Expands Lupin's portfolio of complex generics and injectable products for the U.S. market.
Approval covers single-dose vials of 100 mg/mL concentration.
👀 What to Watch
Investors should monitor for the transition from tentative to final approval, which will depend on the expiration of innovator patents. This development is a positive indicator of Lupin's R&D capabilities in the complex injectable space.
Lupin Increases Stake in Philippines Subsidiary MPPI to 56.28% via Buyback
Lupin Limited's indirect subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), has completed a buyback of 2,813,811 equity shares from existing shareholders. Lupin's intermediate holding company, Nanomi B.V., did not participate in the buyback, resulting in its stake in MPPI increasing from 51% to 56.28%. MPPI is a profitable entity with a FY25 turnover of PHP 2,096.6 million. This consolidation of ownership was funded through MPPI's retained earnings, requiring no cash outflow from Lupin.
Key Highlights
Indirect shareholding in MPPI increased from 51% to 56.28% effective March 30, 2026.
MPPI bought back 2,813,811 equity shares using its own retained earnings.
MPPI reported a turnover of PHP 2,096.6 million and Net Worth of PHP 1,265.5 million for FY25.
The transaction results in higher earnings consolidation for Lupin without any fresh capital investment.
👀 What to Watch
Investors should view this as a positive structural move that increases Lupin's exposure to the Philippines market without capital expenditure. No immediate action is required, but it strengthens the company's long-term consolidated bottom line.
Lupin Receives U.S. FDA Tentative Approval for Pitolisant Tablets (Generic Wakix)
Lupin Limited has secured tentative approval from the U.S. FDA for its Pitolisant Tablets in 4.45mg and 17.8mg strengths. This product is a generic version of Wakix, which is indicated for the treatment of narcolepsy. The tablets will be manufactured at Lupin's Nagpur facility in India. While the approval is tentative, it marks a significant step in expanding Lupin's CNS portfolio in the U.S. market.
Key Highlights
Received tentative U.S. FDA approval for Pitolisant Tablets (4.45mg and 17.8mg)
Product is bioequivalent to the reference brand drug Wakix®
Manufacturing will be localized at the company's Nagpur facility in India
Strengthens Lupin's presence in the U.S. Central Nervous System (CNS) therapy segment
👀 What to Watch
Investors should view this as a positive development for Lupin's medium-term U.S. pipeline, though they should wait for clarity on the final approval and launch timeline. Monitor the stock for potential gains as the company moves closer to commercializing this narcolepsy treatment.
Lupin Subsidiary LMS Expands Dabhasa Facility to Boost Peptide and CRDMO Capabilities
Lupin Manufacturing Solutions (LMS), a wholly-owned subsidiary of Lupin, has announced a strategic expansion of its Dabhasa facility in India to scale its peptide building-blocks platform. The expansion includes a new block for CRDMO services and two specialized units dedicated to peptide manufacturing. This move targets the high-growth market for complex therapeutics, including peptides and Antibody-Drug Conjugates (ADCs). By strengthening its infrastructure, Lupin aims to capture a larger share of the global advanced pharmaceutical solutions market through its team of over 250 scientists.
Key Highlights
Strategic expansion of Dabhasa facility to scale peptide building-blocks and CRDMO capabilities.
Addition of a new CRDMO block and two specialized units for dedicated peptide manufacturing.
Focus on complex modalities including protected amino acids, peptides, and biologic ADCs.
LMS leverages a team of over 250 scientists to support early development to commercial scale.
Strengthens Lupin's position in the global peptide ecosystem and complex therapeutics market.
👀 What to Watch
Investors should view this as a positive long-term move to diversify into high-margin CDMO and complex generic segments. Monitor the revenue contribution from the LMS subsidiary in upcoming quarters to gauge the execution and scaling of this expansion.
Lupin and Zydus Sign Licensing Deal to Co-market Semaglutide Injection in India
Lupin Limited has entered into a licensing and supply agreement with Zydus Lifesciences to co-market Semaglutide Injection (15 mg/3 ml) in the Indian market. Under the agreement, Lupin will market the product under the brands Semanext and Livarise, while Zydus will continue with its own brands. Lupin is required to pay Zydus upfront licensing fees and milestone-based payments for these semi-exclusive rights. This partnership targets the high-growth segments of Type 2 diabetes and chronic weight management in India.
Key Highlights
Lupin gains semi-exclusive rights to co-market Zydus's innovative Semaglutide Injection (15 mg/3 ml) in India.
Lupin will market the therapy under brand names Semanext and Livarise using a reusable pen device.
The agreement involves Lupin paying Zydus upfront licensing fees and milestone payments.
Therapy targets Type 2 diabetes and obesity management for adults with BMI of 30 kg/m2 or greater.
The partnership leverages Lupin's extensive domestic reach to expand access to GLP-1 therapies.
👀 What to Watch
Investors should view this as a strategic positive as it strengthens Lupin's cardio-metabolic portfolio with a high-demand GLP-1 therapy. Monitor the market share gains and the impact of milestone payments on Lupin's margins in the coming quarters.
Lupin's Ankleshwar Facility Receives US FDA Form-483 with 2 Observations
The U.S. FDA concluded a six-day inspection at Lupin's manufacturing facility in Ankleshwar, India, on March 07, 2026. The inspection resulted in the issuance of a Form-483 with two observations regarding manufacturing practices. Lupin has stated it will address these observations and respond to the regulator within the stipulated timeframe to ensure CGMP compliance. While the number of observations is low, the impact depends on their technical severity and the company's ability to remediate them quickly.
Key Highlights
U.S. FDA inspection conducted at the Ankleshwar facility from March 02 to March 07, 2026.
The inspection concluded with the issuance of a Form-483 containing 2 observations.
Lupin is required to respond to the U.S. FDA within the stipulated timeframe to address findings.
Company maintains commitment to CGMP standards across all manufacturing facilities.
👀 What to Watch
Investors should monitor for the final classification of the inspection (VAI or OAI) as significant observations could lead to regulatory escalations. The low number of observations is generally manageable, but the specific nature of the findings will determine the long-term impact on US exports.
Lupin Delays Acquisition of VISUfarma B.V. to April 2026
Lupin Limited has announced a timeline extension for the acquisition of VISUfarma B.V. by its subsidiary, Nanomi B.V. The transaction, which involves acquiring 100% of the share capital, was previously expected to conclude by February 28, 2026. The company now anticipates completion in April 2026, pending the satisfaction of specific closing conditions. This acquisition is a strategic move to strengthen Lupin's presence in the European pharmaceutical market.
Key Highlights
Acquisition of 100% share capital of Netherlands-based VISUfarma B.V. by Lupin's subsidiary Nanomi B.V.
Completion timeline extended from February 28, 2026, to April 2026.
Delay is attributed to the ongoing fulfillment of specific closing conditions.
Follows previous regulatory updates provided on September 29, 2025, and December 30, 2025.
👀 What to Watch
Investors should view this as a minor procedural delay rather than a deal cancellation. Monitor for the final completion announcement in April 2026 to assess the impact on Lupin's international revenue growth.
Lupin Receives US FDA EIR with Satisfactory VAI Status for Goa Facility
Lupin Limited has successfully received the Establishment Inspection Report (EIR) from the US FDA for its Goa manufacturing facility. The report follows an 11-day inspection conducted from November 10 to November 21, 2025. The facility has been assigned a Voluntary Action Indicated (VAI) classification, which is considered a satisfactory regulatory outcome. This clearance is crucial for Lupin as it ensures the continued supply and potential for new product approvals from this key export site to the US market.
Key Highlights
Received US FDA EIR for the Goa facility with a satisfactory VAI classification.
The inspection was conducted over an 11-day period from November 10 to November 21, 2025.
VAI status indicates that the facility meets regulatory standards despite minor observations.
This clearance supports Lupin's global supply chain and US market growth strategy.
👀 What to Watch
This is a positive development that removes a significant regulatory overhang for the Goa plant. Investors should monitor for potential new product approvals from this site that may have been pending the inspection outcome.
Lupin Ranks #1 Globally in Pharma with 91/100 Score in S&P ESG Assessment 2025
Lupin has achieved the top global rank in the pharmaceutical sector in the 2025 S&P Global Corporate Sustainability Assessment (CSA) with a score of 91 out of 100. This score places Lupin in the top 1% of over 9,200 companies evaluated across 59 industries worldwide. Additionally, the company has been recognized as the leader across all sectors in India, surpassing both domestic and international peers. This marks Lupin's third consecutive year of inclusion in the S&P Sustainability Yearbook, reflecting strong governance and environmental stewardship.
Key Highlights
Achieved a score of 91 out of 100 in the S&P Global Corporate Sustainability Assessment (CSA)
Ranked No. 1 globally in the pharmaceutical industry and No. 1 across all sectors in India
Placed within the top 1% of more than 9,200 companies assessed globally
Included in the Sustainability Yearbook 2026 for the third consecutive year
One of only 848 companies to earn Yearbook inclusion out of 9,200+ assessed
👀 What to Watch
This recognition enhances Lupin's appeal to institutional and ESG-focused investors, potentially leading to increased capital inflows. Investors should consider this a positive indicator of the company's long-term operational resilience and governance standards.
Lupin Ranks #1 Globally in Pharma with 91/100 S&P ESG Score
Lupin Limited has achieved the top global rank in the pharmaceutical sector in the S&P Global Corporate Sustainability Assessment 2025. The company secured a score of 91 out of 100, placing it in the top 1% of companies worldwide. Notably, Lupin also ranked as the leader across all sectors in India, surpassing both domestic and international peers. This marks the third consecutive year Lupin has been included in the S&P Sustainability Yearbook, which features only 848 companies out of over 9,200 assessed.
Key Highlights
Achieved a score of 91/100 in the S&P Global Corporate Sustainability Assessment 2025.
Ranked #1 globally in the pharmaceutical industry and #1 across all sectors in India.
Placed within the top 1% of companies worldwide for sustainability performance.
Included in the S&P Sustainability Yearbook 2026 for the third consecutive year.
Outperformed over 9,200 companies assessed across 59 different industries globally.
👀 What to Watch
Investors should view this as a positive indicator of Lupin's strong governance and risk management, which often attracts long-term institutional capital. It reinforces the company's premium positioning in the ESG-conscious investment landscape.
Lupin Faces GST Inspection and Search at Registered Office in Mumbai
Lupin Limited has reported that the Maharashtra Goods & Service Tax Department initiated an inspection and search at its registered office on February 25, 2026. The search, conducted under Section 67 of the MGST Act, 2017, pertains to the verification of GST payments and Input Tax Credit (ITC) claims. The company is currently cooperating with officials and has stated that there is no immediate impact on its financial or operational activities. Investors should note that such inspections are procedural but can lead to future tax demands if discrepancies are found.
Key Highlights
GST Department initiated search proceedings at Lupin's Mumbai office on February 25, 2026, at 11:50 AM.
The inspection is being conducted under Section 67 of the Maharashtra GST Act, 2017.
Authorities are seeking documents specifically related to GST payments and Input Tax Credit (ITC) claims.
Lupin reports no current quantifiable impact on its financial or operational performance.
The company is extending full cooperation and providing all necessary documentation to the tax officials.
👀 What to Watch
Investors should monitor for subsequent updates regarding any potential tax demands or litigation resulting from this search. No immediate action is required as operations remain unaffected, but tax-related developments can impact future cash flows.
Lupin Launches Brivaracetam Oral Solution in US Targeting $135 Million Market
Lupin Limited has received US FDA approval and commenced the launch of Brivaracetam Oral Solution (10 mg/mL) in the United States. The product is a generic equivalent of UCB's Briviact, used for treating partial-onset seizures in patients aged 1 month and older. According to IQVIA data, the annual sales for this product in the US were approximately USD 135 million as of December 2025. This launch further strengthens Lupin's presence in the US Central Nervous System (CNS) therapeutic segment.
Key Highlights
Received US FDA approval for Brivaracetam Oral Solution 10 mg/mL ANDA
Product is the bioequivalent to Briviact Oral Solution by UCB, Inc.
Targets a US market size estimated at USD 135 million per IQVIA MAT Dec 2025 data
Indicated for partial-onset seizures in patients 1 month of age and older
Immediate launch initiated in the United States market following approval
👀 What to Watch
Investors should monitor the ramp-up of this product as it contributes to Lupin's high-margin US generic portfolio. The launch is a positive development for the company's CNS segment and overall US revenue growth.
